Adagene (Suzhou China) is a clinical stage biotech company with innovative antibody discovery and engineering technologies.
Adagene's vision is to balance mother nature and human engineering to discover and develop innovative antibody therapeutics.
Adagene was founded in 2011 and is headquartered in Suzhou Industrial Park,, Jiangsu, China.
Adagene has developed a proprietary Dynamic Precision Library (DPL) to deliver treatments with increased efficacy and safety. It combines computational biology and artificial intelligence to design novel antibodies that address unmet patient needs. Its wholly owned pipeline is comprised of novel immunotherapy programs with potential to be first or best in class.
Adagene has forged strategic collaborations with reputable global partners that leverage its technology in multiple approaches at the vanguard of science.
Adagene is backed by F-Prime, General Atlantic, Eight Roads, WuXi AppTec, GP Healthcare Capital, New World TMT, Sequoia China and others. The company completed $69M Series D financing on Jan 08, 2020. This new round brings Adagene's total funding to over $150M to date.